Ces Urol 2001, 5(5):12-14 | DOI: 10.48095/cccu2001036
Toxic epidermal necrolysis in a patient treated with trimethoprim/sulfamethoxasol
- FN a LF UK, Hradec Králové
- 1 Urologická klinika
- 2 Oddělení klinické hematologie
- 3 Kožní klinika
- 4 Ústav klinické imunologie a alergologie
- 5 Stomatologická klinika
The authors present the case of 49 year old male treated for the urinal infection with trimethoprim/sulfamethoxasol. The serious toxoallergic reaction developed after 5 days of the treatment. The administration of trimethprim/sulfamethoxasol was stopped and the patient was placed in a room with reversal isolation. Repeated plasma-pheresis followed and complex auxiliary therapy was given. The dermal areas were temporarilly covered with the xenotransplants. The patient was discharged after 25 days.
Keywords: Toxic epidermal necrolysis, Trimethoprim/sulfamethoxasol, Reversal isolation, Plasmapheresis, Xenotransplants
Published: December 1, 2001
References
- Berkow R. Kompendium klinické medicíny (Merck manual). Praha 1996; X-Egem: 2414 - 15.
- Roujeau JC, Kelly JP, Naldi L et al. Medication use and the risk of StevensJohnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333[24]:1600-7.
Go to original source... 
Go to PubMed... - Hunziker T, Kunzi UP, Braunschweig S et al. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy 1997; 52[4]: 388-93. Go to original source... Go to PubMed...
- Vaillant L. Mechanism of cutaneous drug reactions. Rev Pract 2000; 50 [12]: 1294-9.
- Wolkenstein P, Carriere V, Charue D et al. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and StevensJohnson syndrome. Pharmacogenetics 1995; 5[4]: 255-8. Go to original source... Go to PubMed...
- Schulz JT, Scheridan RL, Ryan CM et al. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil 2000; 21[3]: 199-204. Go to original source... Go to PubMed...
- Murphy JT, Purde GF, Hunt JL. Toxic epidermal necrolysis. J Burn Care Rehabil 1997; 18[5]: 417-20. Go to original source...
- Engerhardt SL, Schurr MJ, Helgerson RB. Toxic epidermal necrolysis: an analysis of referral patterns and steroid usage. J Burn Care Rehabil 1997; 18[6]: 520-4. Go to original source...
- Roujeau JC. Treatment of severe drug eruptions. J Dermatol 1999; 26[11]: 718-22. Go to original source... Go to PubMed...
- Roujeau JC. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease with differs from erythema multiforme. J Dermatol 1997; 24[11]: 726-9. Go to original source... Go to PubMed...
- Criton S, Devi K, Sridevi PK et al. Toxic epidermal necrolysis-a retrospective study. Int J Dermatol 1997; 36[12]: 923-5. Go to original source... Go to PubMed...
- Wolkenstein P, Revuz J. Toxic epidermal necrolysis. Dermatol Clin 2000; 18[3]: 485-95. Go to original source... Go to PubMed...
- Bastuji-Garin S, Fouchard N, Bertocchi M et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115[2]: 149-53. Go to original source... Go to PubMed...
- Chan HL, Stern RS, Arndt KA et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A populationbased study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990; 126[1]: 43-7. Go to original source...
- Jick H, Derby LE. A large population-based follow-up study of trimethoprim/sul famethoxasole, trimethoprim, and cephalexin for uncommon serious drug toxicity. Pharmacotherapy 1995; 15[4]: 428-32. Go to original source...
- Garcia-Doval I, LeCleach L, Bocquet H et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000; 136[3]: 323-7. Go to original source... Go to PubMed...
- Gibson CJ, Poduri KR. Heterotopic ossification as a complication of toxic epidermal necrolysis. Arch Phys Med Rehabil 1997; 78[7]: 774-6. Go to original source... Go to PubMed...
- Guillaume JC, Roujeau JC, Revuz J et al. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell´s syndrome). Arch Dermatol 1987; 123[9]: 1166-70. Go to original source...
- Wong KC, Kennedy PJ, Lee S. Clinical manifestations and outcomes in 17 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis. Australs J Dermatol 1999; 40[3]: 131-4. Go to original source... Go to PubMed...
- Egan CA, Grant WJ, Morris SE et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999; 40[3]: 458-61. Go to original source... Go to PubMed...
- Yamada H, Takamori K, Yaguchi H et al. A study of the efficacy of plasmapheresis for the treatment of drug induced toxic epidermal necrolysis. Ther Apher 1998; 2[2]: 153-6. Go to original source... Go to PubMed...
- Furubacke A, Berlin G, Anderson C et al. Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis? Intensive Care Med 1999; 25[11]: 1307-10. Go to original source... Go to PubMed...
- Klein L, Mericka P, Strakova H et al. Biological skin covers in treatment of two cases of the Lyell´s syndrome. Ann Transplant 1997; 2[1]: 45-8.
- Arevalo JM, Lorente JA. Skin coverage with Bionare biomaterial for the treatment of patient with toxic epidermal necrolysis. J Burn Care Rehabil 1999; 20[5]: 406-10. Go to original source... Go to PubMed...
- Vivard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282[5388]: 490-3. Go to original source... Go to PubMed...